ReviewSeminars in immunology2010
Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.
Review in Seminars in immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Research hotspots and trends in tumor vaccine adjuvants: A bibliometric analysis from 2010 to 2024.Human vaccines & immunotherapeutics · 2025Review
- Exploring immunotherapy in colorectal cancer.Journal of hematology & oncology · 2022Review
- Novel Mouse Models for Cancer Immunology.Annual review of cancer biology · 2022Article
- Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.Expert opinion on drug discovery · 2021Review
- Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.Human vaccines & immunotherapeutics · 2020Article
- Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.Nature biotechnology · 2018Article
- Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.Cancer research · 2017Article
- Article
- Immune therapy for human papillomaviruses-related cancers.World journal of clinical oncology · 2014Review
- Article
- Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model.BMB reports · 2014Article
- Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.Immunologic research · 2013Review
- Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.Oncoimmunology · 2013Article
- Tumor-Associated Glycans and Immune Surveillance.Vaccines · 2013Review
- Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro.Human vaccines & immunotherapeutics · 2013Article
- Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers.PloS one · 2012Article
- Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors.PloS one · 2012Article
- Immune microenvironment in tumor progression: characteristics and challenges for therapy.Journal of oncology · 2012Article
- Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.Therapy (London, England : 2004) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.